2023
Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial
Mc Causland F, Hsu J, Himmelfarb J, Ikizler T, Raj D, Mehrotra R, Waikar S, Kimmel P, Kliger A, Dember L, Charytan D, Kliger A, Charytan D, Mc Causland F, Robinson E, Waikar S, Williams M, Weiner D, Aurien-Blajeni E, Cinelli M, Nizam T, Rim S, Seok P, Smith C, Curtis J, Raj D, Regunathan-Shenk R, Sharma S, Ramezani A, Andrews S, Dumadag M, Franco C, Wing M, Himmelfarb J, Mehrotra R, Anderson L, Linke L, Manahan L, Ikizler T, Hung A, Cavanaugh K, Booker C, Brannon B, Clagett A, Ellis C, Dember L, Landis J, Anderson A, Hsu J, Cifelli D, Ballard S, Durborow M, Howard T, Kuzla N, Nessel L, Tierney A, Skali H, Solomon S, Rad A, Di Carli M, Gaber M, Foster C, Kimmel P, Kusek J. Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial. Kidney360 2023, 4: e486-e495. PMID: 36763641, PMCID: PMC10278797, DOI: 10.34067/kid.0000000000000067.Peer-Reviewed Original ResearchConceptsEffect of spironolactoneFrequency of bradycardiaMaintenance hemodialysisFollow-upPost hoc analysisConduction blockArrhythmic eventsCardiovascular eventsMaintenance HDSudden deathHoc analysisIncidence of cardiovascular eventsAssociation of spironolactoneDose of spironolactoneRisk of cardiovascular eventsDouble-blind trialProportion of patientsPatients treated with maintenance HDRandomized controlled trialsGeneralized estimating equation modelsSpironolactone groupPlacebo-controlledSpironolactone treatmentBradycardic eventsAge of participants
2022
A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Dember L, Hung A, Mehrotra R, Hsu J, Raj D, Charytan D, Mc Causland F, Regunathan-Shenk R, Landis J, Kimmel P, Kliger A, Himmelfarb J, Ikizler T, Consortium H. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney International 2022, 102: 1178-1187. PMID: 35863559, PMCID: PMC9588554, DOI: 10.1016/j.kint.2022.06.022.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesPlacebo groupAdverse eventsMedian decreaseHemodialysis patientsIL-6IL-1 receptor antagonistRate of adverse eventsEffect of anakinraPlacebo-controlled trialBaseline to weekAnti-cytokine therapyIL-1 inhibitionAssociated with morbidityAnakinra groupReceptor antagonistBetween-group differencesEfficacy outcomesAnakinraMaintenance hemodialysisRandomized controlled pilot trialChronic inflammationEvaluate safetyPlaceboIL-1Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Tuttle KR, Wong L, St. Peter W, Roberts G, Rangaswami J, Mottl A, Kliger A, Harris RC, Gee PO, Fowler K, Cherney D, Brosius FC, Argyropoulos C, Quaggin SE. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1092-1103. PMID: 35649722, PMCID: PMC9269635, DOI: 10.2215/cjn.02980322.Commentaries, Editorials and LettersConceptsDiabetic kidney diseaseKidney disease careKidney diseaseHealth care systemDisease careKidney failureGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsAngiotensin-converting enzyme inhibitorBreakthrough therapiesMajor public health challengeHealth care system supportCare systemAngiotensin receptor blockersCotransporter 2 inhibitorsHalf of patientsPocket drug costsIndividual health care systemsPublic health challengeHealth care professionalsValue-based careEligible patientsMineralocorticoid antagonistsCardiovascular events
2021
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius FC, Cherney D, Gee PO, Harris RC, Kliger A, Tuttle KR, Quaggin SE. Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2021, 16: 1590-1600. PMID: 34103350, PMCID: PMC8499007, DOI: 10.2215/cjn.18641120.Commentaries, Editorials and LettersConceptsRenin-angiotensin system inhibitorsDiabetic kidney diseaseIrbesartan Diabetic Nephropathy TrialCare of patientsKidney diseaseSystem inhibitorsNew therapiesAngiotensin II Antagonist Losartan (RENAAL) trialAngiotensin II type 1 receptor blockerDiabetic kidney disease progressionType 1 receptor blockerCardiovascular protective therapiesReduction of EndpointsKidney disease progressionKidney protective effectsRenin-angiotensin systemDiabetic Nephropathy TrialRisk of deathHigh residual riskHealth care providersPowerful new therapiesNephropathy TrialReceptor blockersDevastating complicationAntihypertensive agentsThe Microbiome and p-Inulin in Hemodialysis: A Feasibility Study.
Raj D, Sohn M, Charytan D, Himmelfarb J, Ikizler T, Mehrotra R, Ramezani A, Regunathan-Shenk R, Hsu J, Landis J, Li H, Kimmel P, Kliger A, Dember L. The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. Kidney360 2021, 2: 445-455. PMID: 35369018, PMCID: PMC8786005, DOI: 10.34067/kid.0006132020.Peer-Reviewed Original ResearchConceptsGut microbiomeStool samplesMicrobiome compositionMetabolomic profilesCLINICAL TRIAL REGISTRY NAMEWeighted UniFrac distancesStudy of patientsTRIAL REGISTRY NAMEUniFrac distancesMicrobiome diversityPretreatment to post-treatmentMaintenance hemodialysisUremic toxicityClinical trialsIntestinal microbiomeMicrobiomePost-treatmentREGISTRY NAMEGutPatientsHemodialysisMetabolome compositionFrequent sample collectionRegistration numberESKD
2020
Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.
Charytan D, Hsu J, Mc Causland F, Waikar S, Ikizler T, Raj D, Landis J, Mehrotra R, Williams M, DiCarli M, Skali H, Kimmel P, Kliger A, Dember L, Himmelfarb J, Anderson A, Hung A, Sharma S, Weiner D. Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360 2020, 1: 1380-1389. PMID: 35372900, PMCID: PMC8815530, DOI: 10.34067/kid.0004342020.Peer-Reviewed Original ResearchConceptsIsosorbide dinitrateCoronary flow reserveAdverse eventsMaintenance HDMitral annular e' velocityDouble-blind pilot trialFlow reserveRecurrent intradialytic hypotensionRandomized to placeboMaximum tolerated doseTissue Doppler echocardiographyParticipants discontinued therapyGastrointestinal side effectsDetect between-group differencesPilot trialIntra-dialytic hypotensionPlacebo-ControlledPositron emission tomographyDose escalationHeart failure mortalityDose reductionStudy medicationTolerated dosePlacebo groupCombination therapy
2010
In-Center Hemodialysis Six Times per Week versus Three Times per Week
Chertow G, Levin N, Beck G, Depner T, Eggers P, Gassman J, Gorodetskaya I, Greene T, James S, Larive B, Lindsay R, Mehta R, Miller B, Ornt D, Rajagopalan S, Rastogi A, Rocco M, Schiller B, Sergeyeva O, Schulman G, Ting G, Unruh M, Star R, Kliger A. In-Center Hemodialysis Six Times per Week versus Three Times per Week. New England Journal Of Medicine 2010, 363: 2287-2300. PMID: 21091062, PMCID: PMC3042140, DOI: 10.1056/nejmoa1001593.Peer-Reviewed Original ResearchConceptsLeft ventricular massPhysical health composite scoresFrequent hemodialysisComposite outcomeVascular accessVentricular massSelf-reported depressionConventional hemodialysisCardiac magnetic resonance imagingConventional hemodialysis groupErythropoiesis-stimulating agentsRate of hospitalizationSerum albumin concentrationComposite scoreSelf-reported physical healthCognitive performanceMagnetic resonance imagingMaintenance hemodialysisSecondary outcomesBlood pressureLaboratory markersCenter hemodialysisClinical trialsMineral metabolismHealth Survey
2001
PARAMETERS OF HIGH BONE-TURNOVER PREDICT BONE LOSS IN RENAL TRANSPLANT PATIENTS: A LONGITUDINAL STUDY1,2
Cruz D, Wysolmerski J, Brickel H, Gundberg C, Simpson C, Mitnick M, Kliger A, Lorber M, Basadonna G, Friedman A, Insogna K, Bia M. PARAMETERS OF HIGH BONE-TURNOVER PREDICT BONE LOSS IN RENAL TRANSPLANT PATIENTS: A LONGITUDINAL STUDY1,2. Transplantation 2001, 72: 83-88. PMID: 11468539, DOI: 10.1097/00007890-200107150-00017.Peer-Reviewed Original ResearchConceptsBone mineral densityPosttransplant bone lossRenal transplant recipientsLong-term renal transplant recipientsDual-energy X-ray absorptiometryRenal transplant patientsBone lossTransplant recipientsBone resorptionBiochemical markersTransplant patientsLumbar spineLong-term renal transplant patientsEnergy X-ray absorptiometryAccelerated bone resorptionElevated urinary levelsUse of cyclosporineElevated biochemical markersPrevious cross-sectional studiesCross-sectional studyX-ray absorptiometryStable bone massPostrenal transplantationAntiresorptive therapyKidney transplantationIdentification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis
Wuerth D, Finkelstein S, Ciarcia J, Peterson R, Kliger A, Finkelstein F. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. American Journal Of Kidney Diseases 2001, 37: 1011-1017. PMID: 11325684, DOI: 10.1016/s0272-6386(05)80018-6.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic peritoneal dialysisBeck Depression InventoryAntidepressant medicationClinical depressionPsychiatric interviewerPeritoneal dialysisBDI scoresFurther evaluationMortality of patientsCohort of patientsHamilton Depression ScaleTreatment of depressionSelf-administered questionnaireRenal diseasePatient populationDepression ScaleLarge cohortPsychiatric interviewPatientsPossible therapyMedicationsDepression InventoryPilot studyTherapyPatient Safety in End-Stage Renal Disease: How Do We Create a Safe Environment?
Kliger A, Diamond L. Patient Safety in End-Stage Renal Disease: How Do We Create a Safe Environment? Advances In Kidney Disease And Health 2001, 8: 131-137. PMID: 11349254, DOI: 10.1053/jarr.2001.23991.Commentaries, Editorials and LettersContinuous peritoneal dialysis and the extended care facility
Carey H, Chorney W, Pherson K, Finkelstein F, Kliger A. Continuous peritoneal dialysis and the extended care facility. American Journal Of Kidney Diseases 2001, 37: 580-587. PMID: 11228183, DOI: 10.1053/ajkd.2001.22084.Peer-Reviewed Original ResearchConceptsContinuous peritoneal dialysisExtended care facilitiesPeritoneal dialysisCare facilitiesEnd-stage renal diseaseLong-term patient managementPeritoneal dialysis nursesElderly patientsPeritonitis rateTechnique failureRenal diseaseDialysis nursesNephrology staffPatient managementOutcome measuresNursing homesGeriatric facilitiesPatientsDisproportionate increaseDialysisCareHospitalizationTherapyEducation programsMortality
2000
POSTTRANSPLANT BONE DISEASE: EVIDENCE FOR A HIGH BONE RESORPTION STATE
Cayco A, Wysolmerski J, Simpson C, Mitnick M, Gundberg C, Kliger A, Lorber M, Silver D, Basadonna G, Friedman A, Insogna K, Cruz D, Bia M. POSTTRANSPLANT BONE DISEASE: EVIDENCE FOR A HIGH BONE RESORPTION STATE. Transplantation 2000, 70: 1722-1728. PMID: 11152104, DOI: 10.1097/00007890-200012270-00011.Peer-Reviewed Original ResearchConceptsLong-term renal transplant recipientsRenal transplant recipientsBone mineral densityTransplant recipientsBone lossBone resorptionFirst post-transplant yearCumulative prednisone doseElevated urinary levelsIntact parathyroid hormonePercent of patientsDuration of dialysisPost-transplant yearPrevalence of osteoporosisCross-sectional studyLoss of boneBone resorption statePrednisone doseYear posttransplantIntact PTHRenal transplantLevels of calciumRenal functionSerum levelsTransplant yearChronic renal insufficiency: Current understandings and their implications
Bolton W, Kliger A. Chronic renal insufficiency: Current understandings and their implications. American Journal Of Kidney Diseases 2000, 36: s4-s12. PMID: 11118153, DOI: 10.1053/ajkd.2000.19926.Commentaries, Editorials and LettersConceptsChronic renal insufficiencyHealthy People 2010Kidney diseaseComorbid conditionsRenal replacement therapyChronic kidney diseaseCare of patientsClear diagnostic criteriaPopulation-based surveyAvailable epidemiologic dataHealth care resourcesPractical screening testHealth care systemExpeditious referralRenal dysfunctionRenal insufficiencyUremic complicationsCreatinine levelsKidney failureReplacement therapyAppropriate referralBlack raceOptimal careSpecialty careMale genderIncidence of Peritonitis in Chronic Peritoneal Dialysis Patients Infused with Intravenous Iron Dextran
Allen J, Troidle L, Juergensen P, Kliger A, Finkelstein F. Incidence of Peritonitis in Chronic Peritoneal Dialysis Patients Infused with Intravenous Iron Dextran. Advances In Peritoneal Dialysis 2000, 20: 674-678. PMID: 11216558, DOI: 10.1177/089686080002000616.Peer-Reviewed Original ResearchConceptsChronic peritoneal dialysis patientsPeritoneal dialysis patientsPeritonitis episodesCPD patientsIron therapyDialysis patientsStudy populationEnd-stage renal disease patientsDialysis Outcomes Quality Initiative guidelinesIntravenous iron-dextran therapyIntravenous iron dextranIncidence of peritonitisOral iron therapyRisk of peritonitisQuality Initiative guidelinesRenal disease patientsEpisodes of peritonitisIron replacement therapyOutpatient hospital settingIron dextran therapyTransferrin saturation levelsCause of deathNumber of episodesRisk of infectionSpectrum of organismsResidual Renal Function in a Large Cohort of Peritoneal Dialysis Patients: Change over Time, Impact on Mortality and Nutrition
Shemin D, Bostom A, Lambert C, Hill C, Kitsen J, Kliger A. Residual Renal Function in a Large Cohort of Peritoneal Dialysis Patients: Change over Time, Impact on Mortality and Nutrition. Advances In Peritoneal Dialysis 2000, 20: 439-444. PMID: 11007376, DOI: 10.1177/089686080002000411.Peer-Reviewed Original ResearchConceptsWeekly renal Kt/VRenal Kt/VResidual renal functionSerum albumin levelRenal creatinine clearanceKt/VKt/V ureaPeritoneal dialysis patientsCreatinine clearanceRenal functionPD patientsAlbumin levelsSolute clearanceDialysis patientsRenal clearanceTotal Kt/V ureaNutritional statusMean serum albumin levelTotal creatinine clearanceGood nutritional statusDiabetic statusCCR groupDialysis unitsLarge cohortPatientsTidal peritoneal dialysis: Comparison of different tidal regimens and automated peritoneal dialysis
Juergensen P, Murphy A, Pherson K, Kliger A, Finkelstein F. Tidal peritoneal dialysis: Comparison of different tidal regimens and automated peritoneal dialysis. Kidney International 2000, 57: 2603-2607. PMID: 10844630, DOI: 10.1046/j.1523-1755.2000.00120.x.Peer-Reviewed Original ResearchConceptsTidal peritoneal dialysisPKt/VContinuous ambulatory peritoneal dialysisGroup I patientsGroup II patientsDuration of therapyPeritoneal dialysis patientsPeritoneal dialysisDialysis patientsI patientsII patientsDialysis unitsNational Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) Clinical Practice GuidelinesSeparate daysDialysis solutionResidual renal function declinesPD solutionsDialysate volumeWeekly Kt/VPeritoneal dialysis clearanceRenal function declineAmbulatory peritoneal dialysisClinical practice guidelinesKt/VDialysis clearanceAutomated Peritoneal Dialysis: Clinical Prescription and Technology
Ronco C, Kliger A, Amici G, Virga G. Automated Peritoneal Dialysis: Clinical Prescription and Technology. Advances In Peritoneal Dialysis 2000, 20: 70-76. PMID: 10911647, DOI: 10.1177/089686080002002s14.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPatient assessment of quality of care in a chronic peritoneal dialysis facility
Wuerth D, Finkelstein S, Kliger A, Finkelstein F. Patient assessment of quality of care in a chronic peritoneal dialysis facility. American Journal Of Kidney Diseases 2000, 35: 638-643. PMID: 10739784, DOI: 10.1016/s0272-6386(00)70010-2.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic peritoneal dialysisPercentage of patientsPatient satisfactionPatients' perceptionsDialysis facilitiesPeritoneal dialysisPatient responseExit-site infectionPeritoneal dialysis programPhysician-patient interactionNurse-patient interactionLong-term acceptanceCPD therapyCPD patientsRenal diseasePatient assessmentPresent studyDialysis programPrimary nurseDialysis unitsPatientsPsychosocial stressAreas of satisfactionAreas of dissatisfaction
1999
Challenges of Managing Chronic Peritoneal Dialysis-Associated Peritonitis
Troidle L, Kliger A, Finkelstein F. Challenges of Managing Chronic Peritoneal Dialysis-Associated Peritonitis. Advances In Peritoneal Dialysis 1999, 19: 315-318. PMID: 10507811, DOI: 10.1177/089686089901900406.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEffect of Duration of Chronic Peritoneal Dialysis Therapy on the Development of Peritonitis
Troidle L, Gorban–Brennan N, Kliger A, Finkelstein F. Effect of Duration of Chronic Peritoneal Dialysis Therapy on the Development of Peritonitis. Advances In Peritoneal Dialysis 1999, 19: 376-379. PMID: 10507821, DOI: 10.1177/089686089901900416.Peer-Reviewed Original ResearchConceptsDevelopment of peritonitisChronic peritoneal dialysis therapyCPD therapyGroup of patientsPeritoneal dialysis therapyGroup 1Group 3Group 2Dialysis therapyStudy periodCharts of patientsPeripheral vascular diseaseEpisodes of peritonitisOnset of peritonitisCoronary artery diseaseIncidence of deathRate of peritonitisOut-patient unitPeritoneal macrophage functionStaphylococcus aureus peritonitisPeritoneal membrane structureSpectrum of organismsArtery diseaseDiabetes mellitusRetrospective review